TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01175018
Drug: Anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra 100 mg s.c. daily for 14 days
Study: NCT01866293
Drug: Cabozantinib (XL184)
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01010061
Drug: obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
Study: NCT01010061
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m\^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6.
Study: NCT00607594
Drug: saracatinib
Normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive AZD0530 (saracatinib) PO QD in the absence of disease progression or unacceptable toxicity.
Study: NCT01010061
Drug: chlorambucil
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
Study: NCT04179734
Drug: Bremelanotide
Normalized name: Bremelanotide
DrugBank: Bremelanotide (DB11653)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melanocortin-4 receptor agonist subcutaneous injection.
Study: NCT03691233
Drug: Clinical audit on diagnosis and management of neonatal shock
Normalized name: Foreskin fibroblast (neonatal)
DrugBank: Neon (DB11589)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intervenous
Study: NCT03979508
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02775812
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03960775
Drug: dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine infusion (0.4㎍/kg/hr) from anesthetic induction until the start of closure of peritoneum.
Study: NCT03960775
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline infusion during same time period.
Study: NCT00351832
Drug: Vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT03113422
Drug: Induction Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 cycle = 28 days.~* Cycle 1-6: Obinutuzumab IV. Cycle 1, Day 1 obinutuzumab 100 mg and Cycle 1, Day 2 obinutuzumab 900 mg for total dose of 1000 mg. On Cycle 1, Day 8 and Day 15 obinutuzumab 1000 mg. Starting with Cycle 2, obinutuzumab 1000 mg on Day 1 only of each cycle.~* Cycle 1-6: Bendamustine 90 mg/m² IV on Days 1 and 2 of each cycle over 15 minutes after obinutuzumab.~* Cycle 2-6: Venetoclax 800 mg by mouth daily on Days 1-10 administered before obinutuzumab and/or bendamustine.
Study: NCT03113422
Drug: Maintenance Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients whose disease is the same or improved will receive venetoclax 800 mg by mouth daily for 24 cycles (1 cycle=1 month) and obinutuzumab 1000 mg IV every 2 months for 12 cycles. Patients with no evidence of disease will receive obinutuzumab 1000 mg IV every 2 months for 12 cycles.
Study: NCT03623230
Drug: Bupivacaine 0.25% Injectable Solution
Normalized name: BUPivacaine 0.25% injectable solution
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perineural Injection
Study: NCT03623230
Drug: Bupivacaine 0.125% Injectable Solution
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perineural Injection
Study: NCT00707408
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daily dosing of imatinib 600 mg/day is planned for one month or until progression of disease. Dose increase to 800 mg/ day imatinib is permitted for 2 additional months in the event of response failure. Novartis provided supplies of imatinib for all patients included in the study.
Study: NCT03359356
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A total of 24 doses
Study: NCT00308048
Drug: Pegylated Interferon alfa 2b and ribavirin
Normalized name: Interferon Alfa-2B
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00251979
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00151489
Drug: pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00865592
Drug: dutogliptin
Normalized name: Dutogliptin
DrugBank: Dutogliptin (DB11723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dutogliptin 400 mg, once daily tablet
Study: NCT00163514
Drug: Ciclesonide
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02458040
Drug: Drug selected in the study
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02326454
Drug: talaporfin sodium
Normalized name: Talaporfin
DrugBank: Talaporfin (DB11812)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 1 mg/kg
Study: NCT02326454
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03107520
Drug: Lumason
Normalized name: Lumason
DrugBank: Sulfur hexafluoride (DB11104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of Lumason contrast agent to improve visualization of epiphyseal vascularity in the femoral head.
Study: NCT02288936
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide 160 mg/day
Study: NCT03033537
Drug: Verapamil
Normalized name: Verapamil
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local treatment of erectile dysfunction
Study: NCT01351935
Drug: AVL-292
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Avlocardyl Retard]
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 125 mg to 625 mg orally, once a day, for 28 days (28 days equals 1 cycle). Number of cycles: until progression or unacceptable toxicity develops
Study: NCT00637884
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01539681
Drug: Sorafenib (Nexavar, BAY43-9006)
Normalized name: sorafenib 200 MG [Nexavar]
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects should be treated with sorafenib in compliance with the recommendations written in the local product information.However, the decision on the duration and dose of treatment is at the discretion of the prescribing physician.
Study: NCT03520517
Drug: BHV-0223
Normalized name: BHV-5000
DrugBank: BHV-5000 (DB17817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BHV-0223, 40 mg BID
Study: NCT00772161
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of two extended-release formulations of 20mg Methylphenidate in a cross-over design.
Study: NCT04627467
Drug: Chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250mg tablet (150mg base chloroquine)
Study: NCT01878292
Drug: Vilazodone
Normalized name: Vilazodone
DrugBank: Vilazodone (DB06684)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vilazodone tablets, 15 mg per day, oral administration
Study: NCT04022915
Drug: 64Cu-FBP8
Normalized name: 64Cu-dotatate
DrugBank: Copper oxodotreotide Cu-64 (DB15873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 10 mCi (millicurie) 64Cu-FBP8 will be administered to each subject.
Study: NCT04065555
Drug: TAK-981
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral microdose injection by the CIVO device.
Study: NCT01878292
Drug: Vilazodone
Normalized name: Vilazodone
DrugBank: Vilazodone (DB06684)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vilazodone tablets, 30 mg once per day, oral administration
Study: NCT01494532
Drug: ropinirole/L-dopa
DrugBank: Ropinirole (DB00268)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ropinirole as adjunctive therapy with L-dopa
Study: NCT02933034
Drug: Manganese-enhanced MRI contrast reagent
DrugBank: Manganese citrate (DB14495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI using manganese-enhanced MRI contrast reagent (manganese 0.28 mL/kg).
Study: NCT02933034
Drug: Gadolinium-enhanced MRI contrast reagent
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI using gadolinium-enhanced MRI contrast reagent (gadolinium 0.2 mmol/kg).
Study: NCT04252846
Drug: Perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perampanel oral tablets or oral suspension.
Study: NCT04631575
Drug: SHR6390
Normalized name: Cdk4/6 inhibitor shr6390
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR6390, PO,single-dose
Study: NCT01230307
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months
Study: NCT01647451
Drug: NNC0114-0006
Normalized name: NNC0114-0006
DrugBank: NNC0114-0006 (DB18361)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two i.v. (intravenous) doses administered 6 weeks apart.
Study: NCT00898807
Drug: citalopram
Normalized name: Citalopram
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: target dose 30mg daily for 9 weeks
Study: NCT03226145
Drug: Bisacodyl
Normalized name: Bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given as agent to monitor effect on symptoms and then to compare with motility data. Drug itself not being tested.
Study: NCT03226145
Drug: Hyoscine butylbromide
Normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given as agent to monitor effect on symptoms and then to compare with motility data. Drug itself not being tested.
Study: NCT02120547
Drug: Cenicriviroc in mild liver impaired
DrugBank: Cenicriviroc (DB11758)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with mild hepatic impairment will receive CVC, 1 tablet once daily, for 14 days. Matching healthy subjects will receive CVC, 1 tablet once daily, for 14 days.
Study: NCT02120547
Drug: Cenicriviroc in moderate liver impaired
Normalized name: LIVER
DrugBank: Cenicriviroc (DB11758)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with moderate hepatic impairment will receive CVC, 1 tablet once daily, for 14 days. Matching healthy subjects will receive CVC, 1 tablet once daily, for 14 days.
Study: NCT00056407
Drug: Dutasteride
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily dosing of 0.5mg of dutasteride orally for up to 4 years.
Study: NCT01388660
Drug: Cloas
Normalized name: CYCLOASTRAGENOL
DrugBank: Cyclo(his-pro) (DB02414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A tablet containing 75 mg of Clopidogrel and 100 mg of Aspirin, PO, 2 tablet once daily for Period I \& II Day 1 (crossover manner)
Study: NCT00446563
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 160 mg film coated tablets taken orally once daily in the morning.
Study: NCT00446563
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg or 10 mg tablets taken orally once daily in the morning.
Study: NCT00446563
Drug: Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12.5 mg or 25 mg tablets taken orally once daily in the morning.
Study: NCT00446563
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg tablets taken orally once daily in the morning.
Study: NCT00527475
Drug: ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.5 mg. given as an intraocular injection
Study: NCT00527475
Drug: verteporfin
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Standard dosage of 6 mgs. / meter2 of body surface area given intravenously.
Study: NCT00971178
Drug: Peripheral normal saline
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same volume of normal saline as dexmedetomidine is infiltrated and IV infusion.
Study: NCT01499602
Drug: Norethisterone Acetate tablets
Normalized name: ethisterone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norethisterone Acetate tablets at a dose of 5 mg three times daily (15mg/day) for 3 weeks over three months.With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months
Study: NCT01626391
Drug: TRx0237
Normalized name: TRX0237 dimesylate
DrugBank: Hydromethylthionine mesylate (DB16899)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRx0237 tablets 250 mg/day (given as 125 mg bid) for 4 weeks
Study: NCT02431065
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:~1. Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.~2. Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.~3. Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.
Study: NCT00597480
Drug: rhGH (Norditropine SimpleXx®)
Normalized name: rhGH
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the recommended dose in the EU of rhGH (Norditropine SimpleXx®
Study: NCT02740647
Drug: Amoxicillin Clavulanate
Normalized name: amoxicillin / clavulanate
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: getting intra-venous1GR Amoxicillin Clavulanate 3 times a day for 5 days post surgery
Study: NCT00001835
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01476475
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (100 U/ml) was self-administered by SC injection before breakfast using pen-type injector (Lantus® Solostar®). The initial daily dose of insulin glargine was 10 U and then dose was adjusted weekly to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L).
Study: NCT02411903
Drug: atorvastatin and clopidogrel
Normalized name: Atorvastatin and clopidogrel only product
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose: atorvastatin 40mg/d plus clopidogrel 75mg/d for 9 months.
Study: NCT03391284
Drug: acetominophen
Normalized name: acetominophen 500 MG / dextromethorphan HBr 15 MG / doxylamine succinate 6.25 MG / pseudoephedrine HCl 30 MG per 15 ML Oral Solution
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: INTRAVENOUS
Study: NCT03719690
Drug: Tipifarnib
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet for oral administration
Study: NCT00004998
Drug: Lamivudine/Zidovudine
Normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03480321
Drug: Cilostazol 100 mg
Normalized name: cilostazol 100 MG
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One immediately-release tablet (Cilostazol 100 mg) at 08:00 and another at 20:00, twice daily oral dose (total daily dose of 200 mg)
Study: NCT00004998
Drug: Capravirine
Normalized name: Capravirine
DrugBank: Capravirine (DB08502)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004998
Drug: Nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00099970
Drug: M200 (volociximab) in Combination with Dacarbazine (DTIC)
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01263483
Drug: Alogliptin and voglibose
Normalized name: metformin and alogliptin
DrugBank: Voglibose (DB04878)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
Study: NCT01263483
Drug: Alogliptin and voglibose
Normalized name: metformin and alogliptin
DrugBank: Voglibose (DB04878)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
Study: NCT01263483
Drug: Voglibose
Normalized name: Voglibose
DrugBank: Voglibose (DB04878)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Alogliptin placebo-matching tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
Study: NCT03413280
Drug: Ultrasound guided Rectus sheath block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound guided rectus sheath block with 0.25% ropivacaine 34ml around umbilicus
Study: NCT03413280
Drug: Intercostal nerve block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound guided intercostal nerve block with 0.25% ropivacaine 6ml in 7,8,9 th intercostal space
Study: NCT00159900
Drug: Sildenafil Citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00370032
Drug: alosetron
Normalized name: Alosetron
DrugBank: Alosetron (DB00969)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03445208
Drug: BMS-986036
Normalized name: BMS-986036
DrugBank: Pegbelfermin (DB15365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover administration to abdomen then upper arm
Study: NCT01372384
Drug: erlotinib [Tarceva]
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg orally daily
Study: NCT02037295
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin 125mg orally four times per day for 12 days
Study: NCT01131676
Drug: BI 10773 low dose
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 10773 tablets once daily
Study: NCT01131676
Drug: BI 10773 high dose
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 10773 tablets once daily
Study: NCT03129321
Drug: Econazole Nitrate Cream, 1%
DrugBank: Econazole (DB01127)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02560376
Drug: 68Ga-NOTA-exendin-4
Normalized name: Exendin 4
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 68Ga-NOTA-exendin-4 were injected into the patients before the PET/CT scans
Study: NCT00067028
Drug: Clofarabine 40mg/m^2
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 40 mg/m\^2 by vein over 1 hour daily for 5 days.
Study: NCT00067028
Drug: Idarubicin 10mg/m^2
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/m\^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.~Clofarabine + Idarubicin plus Ara-C:~6 mg/m\^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.
Study: NCT00651846
Drug: Yasmin (DRSP 3mg/EE 0.03 mg)
Normalized name: drospirenone
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The study medication was packaged in 21-tablet blister packs. Each subject kit contained 7 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the treatment group received 21 consecutive days of hormonally active tablets (3mg DRSP/0.03 mgEE). In each treatment cycle 21 tablets (1 tablet daily) have to be taken in sequence, followed by a pill-free interval of 7 days. The treatment period was 7 cycles (28 days per cycle).
Study: NCT00067028
Drug: Clofarabine 22.5mg/m^2
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 22.5 mg/m\^2 by vein over 1 hour daily for 5 days.
Study: NCT00067028
Drug: Idarubicin 6 mg/m^2
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 mg/m\^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.
Study: NCT00901745
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Infusion of up to 30picmol/ml angiotensin II will be infused and respondent vasoconstriction assessed.
Study: NCT00901745
Drug: Noradrenaline infusion
Normalized name: noradrenaline hydrochloride
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion of up to 480 picomol/ml of noradrenaline will be infused.
Study: NCT02384876
Drug: Ephedrine 30mg/10mL injectable solution, single administration, dose : 0.6, 0.8, 1.0, 1.2 and 1.4 mg/kG
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02384876
Drug: Ephedrine 30mg/10mL injectable solution, single administration, dose : 0.1 mg/kG.
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no